EP0797677A1 - Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux - Google Patents
Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenovirauxInfo
- Publication number
- EP0797677A1 EP0797677A1 EP95942249A EP95942249A EP0797677A1 EP 0797677 A1 EP0797677 A1 EP 0797677A1 EP 95942249 A EP95942249 A EP 95942249A EP 95942249 A EP95942249 A EP 95942249A EP 0797677 A1 EP0797677 A1 EP 0797677A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acid
- adenovirus
- motor neurons
- interest
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to the field of gene therapy. It relates more particularly to a new method of treatment of pathologies of the nervous system by transfer of genes into the medullary motor neurons by means of adenoviral vectors.
- viruses used for this purpose there may be mentioned in particular adenoviruses (Le Gai La Salle et al., Science 259, 988-990), herpes viruses, adeno-associated viruses and retroviruses.
- adenoviruses Le Gai La Salle et al., Science 259, 988-990
- herpes viruses adeno-associated viruses
- retroviruses retroviruses.
- the studies described in the prior art show that these vectors, and in particular the adenoviruses, are capable of infecting cells of the central nervous system with very high efficiency.
- the present invention indeed describes a particularly effective method for the selective transfer of genes into the marrow.
- the present invention derives in particular from the demonstration that it is possible to specifically transfer a gene at the level of the motor neurons by administration, at the level of the muscle, of an adenoviral vector incorporating said gene.
- the Applicant has now shown that, in a particularly advantageous manner, the adenoviruses are absorbed at the level of the neuromuscular junctions (motor plates), and transported to the cellular bodies of the motor neurons (ventral horn of the spinal cord) by retrograde transport. along motor neuron axons.
- adenoviral vectors thus constitutes a new very specific method of infection of the motor neurons by retrograde transport, making it possible to precisely target the medullary stage on which it is desired to intervene according to the location of the trauma and / or degeneration.
- the method according to the present invention is very particularly advantageous since it makes it possible, by following a precise mapping of the neuromuscular junctions, to specifically and unilaterally infect the motor neurons of the different medullary functional stages. It also turns out to be much less traumatic than a stereotaxic injection into the medullary parenchyma, which would in any case be more diffuse and not restrictive to motor neurons.
- a first object of the invention therefore resides in the use of a recombinant adenovirus comprising in its genome a nucleic acid of interest for the preparation of a pharmaceutical composition intended for the transfer of said nucleic acid into spinal motor neurons by intramuscular administration.
- the method according to the present invention is very advantageous since it makes it possible to precisely target the motor neurons of each medullary functional stage.
- the administration is carried out in a muscle carrying a nervous connection with said site.
- the present invention It is now possible, by a judicious choice of various injections, to infect, specifically and unilaterally, a large number of spinal motor neurons distributed over the different levels.
- administration into muscles of the upper limbs makes it possible to transfer a gene into the motor neurons at the cervical level; administration in thoracic (pectoral) muscles makes it possible to transfer a gene in the motor neurons at the thoracic level; or administration in muscles of the lower limbs (gastrocnemius) makes it possible to transfer a gene in the motor neurons at the lumbar and sacral levels.
- Other muscles can of course be used for administration at the level of these motor neurons, and other motor neurons can also be targeted. To this end, it is possible to use precise maps of the neuromuscular junctions in order to determine, as a function of the targeted spinal stage, the muscle or muscles most suitable for administration.
- Intramuscular administration of adenovirus can be accomplished in different ways. According to a first embodiment, it is performed by injection at several points of the same muscle so as to concern a very large number of motor plates. This embodiment is particularly effective when the point of insertion of the nerve into the muscle in question cannot be identified. When the nerve insertion point is identifiable, the administration is advantageously carried out by one or more injections at or near said point. According to this embodiment, the efficiency of the transfer is greater because a high proportion of administered vector is absorbed at the neuromuscular junction.
- the intramuscular administration is carried out by injections at several points of the same muscle.
- the intramuscular administration is carried out by injection (s) at or near the point of insertion of the nerve.
- the invention relates to the use of a recombinanf adenovirus comprising in its genome a nucleic acid of interest for the preparation of a pharmaceutical composition intended for the transfer of said nucleic acid into the cervical spinal motor neurons by administration in the muscles of the upper limbs (example: biceps, triceps).
- the invention relates to the use of a recombinant adenovirus comprising in its genome a nucleic acid of interest for the preparation of a pharmaceutical composition intended for the transfer of said nucleic acid into the thoracic spinal motor neurons by administration in the chest muscles (e.g. pectoral).
- the invention relates to the use of a recombinant adenovirus comprising in its genome a nucleic acid of interest for the preparation of a pharmaceutical composition intended for the transfer of said nucleic acid into the lumbar medullary motor neurons and / or sacred by administration in the muscles of the lower limbs (gastrocnemius for example).
- the method according to the invention can be implemented using adenoviruses of various origins. Different serotypes of adeno virus, whose structure and properties vary somewhat, have indeed been characterized.
- adenoviruses of type 2 or 5 Ad 2 or Ad 5
- Ad 2 or Ad 5 adenoviruses of animal origin
- adenoviruses of animal origin which can be used in the context of the present invention, mention may be made of adenoviruses of canine, bovine, murine origin (example: Mavl, Beard et al., Nirology 75 (1990) 81), ovine, porcine , avian or even simian (example: SAN).
- the adenovirus of animal origin is a canine adenovirus, more preferably a CAN2 adenovirus [manhattan or A26 / 61 strain (ATCC NR-800) for example].
- the adenovirus used is an adenovirus of human origin.
- the adenovirus is an adenovirus of animal origin.
- the adenovirus genome includes in particular a repeated inverted sequence (ITR) at each end, an encapsidation sequence (Psi), early genes and late genes.
- ITR inverted sequence
- Psi encapsidation sequence
- the main early genes are contained in the E1, E2, E3 and E4 regions.
- the genes contained in the El region are necessary for viral replication.
- the E4 and L5 regions are involved in viral propagation.
- the main late genes are contained in regions L1 to L5.
- the genome of the Ad5 adenovirus has been fully sequenced and is accessible on the database (see in particular Genebank M73260).
- adenoviral vectors used for the implementation of the present invention comprise ITRs, a sequence allowing the encapsidation and the nucleic acid of interest.
- the genome of the adenovirus used is devoid of all or part of the E1 region.
- the E1 region is indeed essential for viral replication and its inactivation leads to the formation of defective viruses for replication, i.e. unable to replicate autonomously in infected cells.
- the E1 region, or any other viral region considered can be made non-functional by any technique known to a person skilled in the art, and in particular by total removal, substitution, partial deletion, or addition of one or more several bases in the genes considered. Such modifications can be obtained in vitro (on isolated DNA) or in situ, for example, by means of genetic engineering techniques, or by treatment with mutagenic agents.
- the genome of the adenovirus used is devoid of a part of the E1 region corresponding to residues 454 to 3328 (fragment PvuII-BglII) or 382 to 3446 (fragment HinfII-Sau3A).
- the genome of the adenovirus used is also devoid of all or part of the E3 and or E4 region.
- the Applicant has now shown that it is possible to construct vectors carrying these different types of deletions. These additional deletions make it possible to increase the safety of the vector and to increase its capacity.
- the nucleic acid of interest can be inserted at different sites in the adenovirus genome.
- it is inserted at the level of the region E1, E3 or E4.
- the defective recombinant adenoviruses according to the invention can be prepared by any technique known to those skilled in the art (Levrero et al., Gene 101 (1991) 195, EP 185 573; Graham, EMBO J. 3 (1984) 2917).
- Us can be prepared by homologous recombination between an adenovirus and a plasmid carrying inter alia the DNA sequence of interest. Homologous recombination occurs after co-transfection of said adenovirus and plasmid in an appropriate cell line.
- the cell line used must preferably (i) be transformable by said elements, and (ii), contain the sequences capable of complementing the part of the genome of the defective adenovirus, preferably in integrated form to avoid the risks of recombination.
- a line mention may be made of the human embryonic kidney line 293 (Graham et al., J. Gen. Virol. 36 (1977) 59) which contains in particular, integrated into its genome, the left part of the genome an Ad5 adenovirus (12%).
- a first method consists in transfecting the DNA of the recombinant (defective) virus prepared in vitro in a competent cell line, that is to say carrying in trans all the functions necessary for the complementation of the defective virus. These functions are preferably integrated into the genome of the cell, which reduces the risks of recombination, and confers increased stability on the cell line.
- the preferred line is line 293.
- a second approach consists in co-transfecting into a suitable cell line the DNA of the defective recombinant virus prepared in vitro and the DNA of one or more viruses or helper plasmids. According to this method, it is not necessary to have a competent cell line capable of complementing all the defective functions of the recombinant adenovirus. Part of these functions is in fact complemented by the helper virus or viruses. This or these helper viruses are themselves defective.
- the adenoviruses which have multiplied are recovered and purified according to conventional techniques of molecular biology, as illustrated in the examples.
- the adenoviruses are preferably associated with one or more pharmaceutically acceptable vehicles for an injectable formulation.
- pharmaceutically acceptable vehicles for an injectable formulation can be in particular saline solutions (monosodium phosphate, disodium, sodium chloride, potassium, calcium or magnesium, etc. or mixtures of such salts), sterile, isotonic, or dry compositions, in particular lyophilized, which, by addition, as appropriate, of sterilized water or physiological saline, allow the constitution of injectable solutes.
- the doses of virus used for administration can be adapted according to different parameters, and in particular according to the site (muscle) of administration considered, the number of injections, the gene to be expressed, or even the duration of the treatment. wanted.
- the recombinant adenoviruses according to the invention are formulated and administered in the form of doses of between 10 ⁇ and 10- ⁇ pfu, and preferably 10 ⁇ to 10 ⁇ -O pfu.
- pfu plaque forming unit
- plaque forming unit corresponds to the infectious power of a virus solution, and is determined by infection of an appropriate cell culture, and measures, generally after 15 days, the number of plaques of infected cells. The techniques for determining the pfu titer of a viral solution are well documented in the literature.
- the method according to the present invention is particularly advantageous for the treatment of spinal cord injuries or motor neuron degeneration diseases.
- Spinal cord injuries correspond more particularly to sections at the level of the motor neurons which deprive them of their afferents from higher centers and cause their degeneration.
- the transfer of genes coding for growth factors into sub-lesional motor neurons by retrograde transport according to the invention now offers the possibility of reducing or even preventing this degeneration.
- motor neuron neuropathies there may be mentioned, for example, amyotrophic lateral sclerosis, type I spinal muscular atrophies (Werdnig Hoffman disease) type II or III (Kugelberg-Welander disease), bulbar spinal muscular atrophies (such as Kennedy disease).
- the transfer of genes coding for growth factors or other molecules known to exert a neurotrophic effect on the degenerating motor neuron according to the present invention also offers a new path for the treatment of this type of pathology.
- the effectiveness of the process of the invention can in particular be demonstrated on an animal model: model of partial or complete section of the spinal cord, Wobbler mouse (animal model for studying amyotrophic lateral sclerosis (Leestma JE, Am. J.
- mice (“motoneurone degeneration”: animal model for the study of amyotrophic lateral sclerosis (Messer et al., 1992, Genomics, 18, 797-802)) or pmn mice (“progressive motoneurone neuropathy”: animal model for study motor neuron degeneration during development), as illustrated in the examples. Incorporation, tolerance and safety for humans can be tested on in vitro culture models of human embryonic medullary neurons.
- the nucleic acid of interest incorporated into the adenoviral vectors according to the invention preferably codes for a neuroactive substance, that is to say capable of exerting a beneficial effect on nerve cells. It can be a substance capable of compensating for a deficit in or reducing an excess of an endogenous substance, or also a substance which confers on cells new properties. It may more particularly be a growth factor, a neurotrophic factor, a cytokine, a neurotransmitter or even an enzyme, or a neurotr ansmitter or hormone receptor.
- G-CSF colony stimulating factors
- GM-CSF GM-CSF
- M-CSF M-CSF
- CSF fibroblast growth factors
- NEGF cells vascular
- the preferred factors are in particular the ciliary neurotrophic factor (C ⁇ TF), the glial cell maturation factors (GMFa.b) GD ⁇ F, BD ⁇ F, ⁇ T3, NT5, etc.
- the preferred cytokines are interleukins and interferons and, among the enzymes, use is preferably made of the enzymes for biosynthesis of neurotransmitters (tyrosine hydroxylase, acetyl choline transferase, glutamic acid decarboxylase), lysosomal enzymes (hexosaminidases, arylsulfatase, glucocerebrosidase, HGPRT), the enzymes involved in the detoxification of free radicals (superoxide dismutase I, II or III, catalase, gluthation peroxidase).
- the androgen receptors (implicated in Kennedy's disease) will be used, among others.
- the nucleic acid can be of natural or artificial origin. It may especially be genomic DNA (gDNA), complementary DNA (cDNA), hybrid sequences or synthetic or semi-synthetic sequences. It can be of human, animal, plant, bacterial, viral, etc. origin. It can be obtained by any technique known to those skilled in the art, and in particular by screening of banks, by chemical synthesis, or also by mixed methods including chemical or enzymatic modification of sequences obtained by screening of banks. They are preferably cDNA or gDNA.
- the nucleic acid also comprises a promoter region for functional transcription in motor neurons, as well as a region located 3 ′ of the gene of interest, and which specifies a transcriptional end signal and a polyadenylation site. All of these elements constitute the expression cassette.
- the promoter region it may be a promoter region naturally responsible for the expression of the gene considered when it is capable of functioning in the infected cell. They can also be regions of different origin (responsible for the expression of other proteins, or even synthetic).
- they may be promoter sequences of eukaryotic or viral genes. For example, they may be promoter sequences originating from the genome of the cell which it is desired to infect.
- the heterologous nucleic acid may be inserted into the genome of the virus downstream of such a sequence.
- the present invention also relates to a method for the transfer of nucleic acids into motor neurons comprising. Muscular administration of an adenoviral vector incorporating said nucleic acid into its genome.
- the method according to the invention is carried out by injection (s) at several points of the same muscle or, when the insertion point of the nerve is detectable, by one or more injections at or near said point (s)
- FIGURE 1 (PHOTO A):
- ⁇ diffuse labeling of many motoneuronal cell bodies
- A highlighting the typical morphology of motoneurons
- FIGURE 2 (PHOTO B): idem A, higher magnification.
- FIGURE 3 (PHOTO C):
- CGRP Calcitonin Gene Related Peptide
- the study was carried out on a model of partial or complete section of the rat spinal cord practiced at the lower thoracic level having the effect of paralyzing the animal for one or both of its lower limbs.
- Such a section deprives the motor neurons of their afferents from the upper centers and causes their degeneration.
- the adn ⁇ ustration was carried out in such a way as to infect the sub-lesional motor neurons by retrograde transport.
- the viral adeno vector used in this example is the vector Ad.RSV. ⁇ gal.
- This vector lacks the sequences necessary for its replication, but nevertheless comprises the sequences necessary to penetrate into the cells which can be infected with it as well as all of the essential sequences necessary for the packaging of this adenovirus. It also carries, under the control of the RSV promoter, the ⁇ galactosidase gene from E. coli.
- the construction of the defective recombinant adenovirus Ad.RSV ⁇ gal has been described in the literature (Stratford-Perricaudet et al., J. Clin. Invest. 90 (1992) 626).
- the adenovirus Ad.RSVbGal is a defective recombinant adenovirus (deleted from regions E1 and E3) obtained by homologous recombination in vivo between the mutant adenovirus Ad-dl324 (Thimmappaya et al., Cell 31 (1982) 543) and the plasmid pAd.RSVbGal (Akli et al. 1993).
- the plasmid pAd.RSVbGal contains, in the 5 '-> 3' orientation,
- the PvuII fragment corresponding to the left end of the Ad5 adenovirus comprising: the ITR sequence, the origin of replication, the packaging signals and the E1A amplifier; - the gene coding for b-galactosidase under the control of the RSN promoter
- Ad5 adenovirus A second fragment of the genome of the Ad5 adenovirus, which allows homologous recombination between the plasmid pAd.RSVbGal and the adenovirus dl324.
- the plasmid pAd.RSVbGal and the adenovirus dl324 are co-transfected in Ugnea 293 in the presence of calcium phosphate to allow homologous recombination.
- the recombinant adenoviruses thus generated are selected by plaque purification.
- the AD ⁇ of the recombinant adenovirus is amplified in the cell line 293, which leads to a culture supernatant containing the non-purified recombinant defective adenovirus having a titer of approximately 10O pfu / ml.
- the viral particles are then purified by centrifugation on a gradient. cesium chloride according to known techniques (see in particular Graham et al., Virology 52 (1973) 456).
- the adenovirus was then used in purified form in a saline phosphate solution (PBS).
- Ad-RSV-b-Gal adenovirus 10 ⁇ pfu per injection
- 9 ⁇ l of adenovirus are injected per injection site with the Hamilton syringe.
- the animals were sacrificed (4% paraformaldehyde infusion) four days after injection, minimum time for retrograde transport to take place from muscle to spinal cord.
- Three blocks of spinal cord were cut longitudinally at the cervical, thoracic and lumbar levels, in sections 50 mM thick.
- the sections were treated for the revelation of ⁇ -Galactosidase making it possible to highlight the cells having been infected by the virus.
- Certain sections have also undergone an anti-"Calcitonin Gene Related Peptide” immunocytochemistry (CGRP), making it possible to specifically mark the motor neurons.
- CGRP Calcitonin Gene Related Peptide
- ⁇ -Galactosidase has been revealed from its substrate, X-Gal, and the reaction product gives a blue color.
- CGRP Calcitonin Gene Related Peptide
- the anti-CGRP immunocytochemistry coupled with the revelation b-Galactosidase made it possible to demonstrate by a double staining that almost all of the CGRP positive cell bodies (i.e. motor neurons) were infected by the virus (photo C).
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9415014 | 1994-12-13 | ||
FR9415014A FR2727867B1 (fr) | 1994-12-13 | 1994-12-13 | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
PCT/FR1995/001650 WO1996018740A1 (fr) | 1994-12-13 | 1995-12-12 | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0797677A1 true EP0797677A1 (fr) | 1997-10-01 |
Family
ID=9469770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95942249A Ceased EP0797677A1 (fr) | 1994-12-13 | 1995-12-12 | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
Country Status (13)
Country | Link |
---|---|
US (1) | US6632427B1 (fr) |
EP (1) | EP0797677A1 (fr) |
JP (1) | JPH10510428A (fr) |
AU (1) | AU712775B2 (fr) |
BR (1) | BR9510090A (fr) |
CA (1) | CA2208224A1 (fr) |
CZ (1) | CZ180697A3 (fr) |
FI (1) | FI972491A0 (fr) |
FR (1) | FR2727867B1 (fr) |
HU (1) | HUT77258A (fr) |
NO (1) | NO972712D0 (fr) |
SK (1) | SK74597A3 (fr) |
WO (1) | WO1996018740A1 (fr) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
IL130852A0 (en) | 1997-01-17 | 2001-01-28 | Rhone Poulenc Rorer Sa | Adenoviral-vector-mediated gene transfer into medullary motor neurons |
FR2761258B1 (fr) * | 1997-03-26 | 1999-06-11 | Rhone Poulenc Rorer Sa | Procede de stimulation de la regeneration nerveuse |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7468181B2 (en) * | 2002-04-25 | 2008-12-23 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
WO2001036603A2 (fr) * | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Virions de virus adeno-associes recombinants destines au traitement de maladies lysosomales |
DE60138403D1 (de) | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
CA2471812C (fr) * | 2001-12-21 | 2012-09-04 | The Salk Institute For Biological Studies | Transfert genetique retrograde cible sur des neurones moteurs |
US6998118B2 (en) * | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
US7922999B2 (en) | 2006-04-25 | 2011-04-12 | The Regents Of The University Of California | Administration of growth factors for the treatment of CNS disorders |
CN102439149B (zh) | 2009-02-12 | 2018-01-02 | 库尔纳公司 | 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病 |
ES2762610T3 (es) | 2009-02-12 | 2020-05-25 | Curna Inc | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF |
ES2845644T3 (es) | 2009-03-04 | 2021-07-27 | Curna Inc | Tratamiento de enfermedades relacionadas con sirtuina1 (SIRT1) mediante inhibición del transcrito del antisentido natural a sirtuina 1 |
MX2011009751A (es) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2. |
WO2010107740A2 (fr) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Traitement des maladies associées à l'homologue du delta-like 1 (dlk1) par inhibition du transcrit antisens naturel de dlk1 |
CN102459596B (zh) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療 |
CN102575251B (zh) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病 |
KR101703695B1 (ko) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | 전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료 |
CN103221541B (zh) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病 |
KR101702689B1 (ko) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료 |
WO2010148050A2 (fr) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Traitement de maladies liées au gène du collagène par inhibition d'un produit de transcription antisens naturel à un gène du collagène |
CA2765889A1 (fr) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Traitement de maladies associees au recepteur de facteur necrosant des tumeurs 2 (tnfr2) par inhibition de la transcription antisens naturelle de tnfr2 |
CA2765815A1 (fr) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Traitement de maladies associees aux genes lies au syndrome de down par inhibition des genes lies au syndrome de down mediee par le produit de transcription antisens naturel |
US9234199B2 (en) | 2009-08-05 | 2016-01-12 | Curna, Inc. | Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) |
CN102482671B (zh) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病 |
ES2661813T3 (es) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1 |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
CA2782373C (fr) | 2009-12-23 | 2019-03-26 | Opko Curna, Llc | Traitement de maladies associees au facteur de croissance des hepatocytes (hgf) par inhibition de la transcription antisens naturelle en hgf |
ES2585829T3 (es) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63 |
WO2011090740A2 (fr) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | Traitement de maladies liées au facteur respiratoire nucléaire 1 (nrf1) par l'inhibition du produit de transcription antisens naturel de nrf1 |
KR101878501B1 (ko) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | 인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료 |
EP2521785B1 (fr) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition de la transcription antisens naturelle du gène de développement du pancrea pour l'utilisation dans le traitement des maladies du développement du pancréa |
DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
RU2610661C2 (ru) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
CN107988228B (zh) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
CN103068982B (zh) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病 |
EP2625274B1 (fr) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Traitement de maladies liées à la sialidase 4 (neu4) par inhibition du transcrit anti-sens endogène de neu4 |
CA2815212A1 (fr) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Traitement de maladies associees a l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogene de idua |
JP6073795B2 (ja) | 2010-10-27 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | インターフェロン関連発生制御因子1(ifrd1)への天然アンチセンス転写物の阻害によるifrd1関連疾患の治療 |
CN103459599B (zh) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | 通过抑制nanog的天然反义转录物而治疗nanog相关疾病 |
JP6188686B2 (ja) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー,インコーポレイテッド | フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療 |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2015171918A2 (fr) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions et leurs utilisations thérapeutiques |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
US9976143B2 (en) | 2014-10-03 | 2018-05-22 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
EP3359685A1 (fr) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation de l'expression génique et criblage de l'expression de protéines dérégulée |
CA3005245A1 (fr) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Oligomeres antisens pour le traitement du syndrome d'alagille |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
EP3389725B1 (fr) | 2015-12-14 | 2022-04-06 | Cold Spring Harbor Laboratory | Compositions et méthodes pour le traitement de maladies du système nerveux central |
WO2017106377A1 (fr) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Oligomères antisens destinés au traitement du retard mental dominant autosomique 5 et du syndrome de dravet |
CA3005254A1 (fr) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions et procedes pour le traitement de retinite pigmentaire 18 et de retinite pigmentaire 13 |
JP2019500345A (ja) | 2015-12-14 | 2019-01-10 | コールド スプリング ハーバー ラボラトリー | 肝臓病の処置のための組成物および方法 |
CN111278991B (zh) | 2017-08-25 | 2022-04-01 | 斯托克制药公司 | 用于治疗病况和疾病的反义寡聚体 |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
CA3173647A1 (fr) | 2020-05-11 | 2021-11-18 | Isabel AZNAREZ | Oligomeres antisens opa1 pour le traitement de pathologies et de maladies |
BR112023020832A2 (pt) | 2021-04-08 | 2023-12-19 | Marengo Therapeutics Inc | Moléculas multifuncionais ligadas a tcr e seus usos |
AU2022261124A1 (en) | 2021-04-22 | 2023-10-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
WO2023178311A1 (fr) * | 2022-03-18 | 2023-09-21 | The University Of North Carolina At Chapel Hill | Procédés de traitement de troubles sous hypothermie et compositions associées |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2119580A1 (fr) * | 1991-10-01 | 1993-04-15 | George Cachianes | Production d'un facteur neurotrophique gpa |
DE69333057T2 (de) * | 1992-08-07 | 2004-07-08 | Wyeth | Rekombinente Adenoviren-Impfstoffe |
JPH08501686A (ja) * | 1992-09-25 | 1996-02-27 | ローン−プーラン・ロレ・ソシエテ・アノニム | 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター |
ES2249761T3 (es) * | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
NZ269156A (en) * | 1993-07-13 | 1996-03-26 | Rhone Poulenc Rorer Sa | Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy |
-
1994
- 1994-12-13 FR FR9415014A patent/FR2727867B1/fr not_active Expired - Fee Related
-
1995
- 1995-12-12 HU HU9701819A patent/HUT77258A/hu unknown
- 1995-12-12 JP JP8518369A patent/JPH10510428A/ja not_active Ceased
- 1995-12-12 WO PCT/FR1995/001650 patent/WO1996018740A1/fr not_active Application Discontinuation
- 1995-12-12 CA CA002208224A patent/CA2208224A1/fr not_active Abandoned
- 1995-12-12 EP EP95942249A patent/EP0797677A1/fr not_active Ceased
- 1995-12-12 BR BR9510090A patent/BR9510090A/pt not_active Application Discontinuation
- 1995-12-12 AU AU43502/96A patent/AU712775B2/en not_active Ceased
- 1995-12-12 SK SK745-97A patent/SK74597A3/sk unknown
- 1995-12-12 CZ CZ971806A patent/CZ180697A3/cs unknown
-
1997
- 1997-01-17 US US08/785,074 patent/US6632427B1/en not_active Expired - Fee Related
- 1997-06-12 NO NO972712A patent/NO972712D0/no not_active Application Discontinuation
- 1997-06-12 FI FI972491A patent/FI972491A0/fi not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO9618740A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPH10510428A (ja) | 1998-10-13 |
FR2727867B1 (fr) | 1997-01-31 |
SK74597A3 (en) | 1997-12-10 |
AU4350296A (en) | 1996-07-03 |
US6632427B1 (en) | 2003-10-14 |
WO1996018740A1 (fr) | 1996-06-20 |
NO972712L (no) | 1997-06-12 |
CA2208224A1 (fr) | 1996-06-20 |
FI972491A (fi) | 1997-06-12 |
FI972491A0 (fi) | 1997-06-12 |
FR2727867A1 (fr) | 1996-06-14 |
AU712775B2 (en) | 1999-11-18 |
BR9510090A (pt) | 1998-07-14 |
CZ180697A3 (en) | 1997-09-17 |
HUT77258A (hu) | 1998-03-02 |
NO972712D0 (no) | 1997-06-12 |
MX9704102A (es) | 1997-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996018740A1 (fr) | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux | |
EP0593755B1 (fr) | Adenovirus recombinants defectifs exprimant des cytokines pour traitement antitumoral | |
EP0698108B1 (fr) | Vecteurs adenoviraux d'origine animale et utilisation en therapie genique | |
FR2712603A1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
EP0752004B1 (fr) | Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf) | |
EP0775213B1 (fr) | Adenovirus comprenant un gene codant pour la glutathion peroxydase | |
EP1032695B1 (fr) | Vecteurs adenoviraux et methode de reduction des evenements de recombinaison homologue | |
EP0687184B1 (fr) | Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires | |
CA2211039C (fr) | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes | |
WO1995014101A1 (fr) | Adenovirus recombinants pour la therapie genique des cancers | |
WO1997019182A1 (fr) | Production de vecteurs retroviraux par l'intermediaire de vecteurs herpetiques | |
FR2724846A1 (fr) | Methode de traitement des cancers par regulation de l'activite des proteines ras | |
US20110178282A1 (en) | Methods and compositions for cancer therapy using a novel adenovirus | |
FR2725213A1 (fr) | Vecteurs viraux et utilisation en therapie genique | |
US20020031493A1 (en) | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) | |
WO2000028062A1 (fr) | Nouveau systeme de regulation de l'expression d'un transgene | |
EP1681354A2 (fr) | Virus recombinants codant pour une activité glutamate décarboxylase (GAD) | |
FR2748753A1 (fr) | Nouveaux vecteurs adenoviraux pour la therapie genique | |
KR20060054290A (ko) | 신규한 아데노바이러스를 이용한 암 치료 방법 및 조성물 | |
FR2717496A1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
EP1053341A1 (fr) | Utilisation d'elements de regulation negative pour l'expression neurospecifique de transgenes | |
MXPA97004102A (en) | Transfer of genes in the medular motoneurons by means of adenovira vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970606 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: SI PAYMENT 970606 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE Owner name: AVENTIS PHARMA S.A. |
|
17Q | First examination report despatched |
Effective date: 20010518 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20040306 |